A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication

International Angiology

Volumn 20, Issue 1, 2001, Pages 58-65

  Kieffer, E ^a   Bahnini, A ^a   Mouren, X ^a   Gamand, S ^a  

^a Division Oberval   (France)

Author keywords

Intermittent claudication; Peripheral vascular diseases, drug therapy; Vasoactive agents

Indexed keywords

NAFTIDROFURYL; PLACEBO;

ADULT; ADVERSE DRUG REACTION; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; FOLLOW UP; GENDER; GEOMETRY; HUMAN; INCIDENCE; INTERMITTENT CLAUDICATION; MALE; OUTCOMES RESEARCH; OUTPATIENT; PATIENT SELECTION; PRACTICE GUIDELINE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; TREADMILL; VASCULAR DISEASE; WALKING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; NAFRONYL; PAIN; PLACEBOS; TREATMENT OUTCOME; VASODILATOR AGENTS; WALKING;

EID: 0034949033     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Management of peripheral arterial disease (PAD). Trans-Atlantic inter-Society Consensus (TASC)
2. Intermittent claudication. Current results of non-operative management
3. Quality of life analysis in patients with lower limb ischaemia: Suggestions for European standardisation
4. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes study
5. ABC of arterial and vascular disease. Secondary prevention of peripheral arterial disease
6. Clinical investigation of drugs for the treatment of chronic peripheral arterial disease
7. Note for guidance on the clinical investigation of individual products in the treatment of chronic peripheral arterial occlusive disease CPMP/EWP/233/95 final
8. Trans-Atlantic conference on clinical trial guidelines in PAOD (Peripheral Arterial Occlusive Disease) clinical trial methodology
9. Naftidrofuryl bei arterieller Verschlusskrankheir
10. Treatment in chronic arterial disease. Results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg
11. Klinischer Wirksamkeitsnachweis von Naftidrofuryl bei Claudicatio intermittens
12. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl, results after 6 months of a controlled multicenter study
13. Impact of intermittent claudication on quality of life
14. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis
15. Exercise training improves functional status in patients with peripheral arterial disease
16. An epidemiological study on the value and limits of physical therapy/exercise training in Fontaine Stage II arterial occlusive disease
17. Exercise for intermittent claudication
18. Exercise therapy for intermittent claudication: A review of the quality of randomised clinical trials and evaluation of predictive factors
19. Effect of daily muscle exercise in patients with intermittent claudication
20. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease
21. Drug therapy for peripheral vascular disease
22. The effects of naftidrofuryl on quality of life
23. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication
24. Naftidrofuryl on quality of life (NIQOL). A Belgian study
25. Is percutaneous transluminal angioplasty better than exercise for claudication. Preliminary results from a prospective randomised trial